A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer

Cancer Journal from Scientific American

Volumn 4, Issue 1, 1998, Pages 46-51

  Vokes, Everett E ^a,f   Figlin, Robert ^b   Hochster, Howard ^c   Lotze, Michael ^d   Rybak, Mary Ellen ^e  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CISPLATIN; DOCETAXEL; RECOMBINANT INTERLEUKIN 4; SCH 39400; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-4; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 0031890315     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
2. Grilli R, Oxman AD, Julian JM. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872.
3. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342:19-21.
4. Vokes EE, Bitran JD. Non-small cell lung cancer: towards the next plateau [editorial]. Chest 1994;106:659-661.
5. Cormier Y, Bergeron D, La Forge J et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982;50:845-849.
6. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
7. Quoix E, Dietemann A, Charbonneau J et al. La chimiotherapie comportant due cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? resultants d'une etude randomisee. Bull Cancer (Paris) 1991;78:341-346.
8. Ganz PA, Figlin RA, Haskell CM et al. for the UCLA Solid Tumor Study Group. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer: does chemotherapy make a difference? Cancer 1989;63:1271-1278.
9. Woods RL, Williams CJ, Levi J et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990;61:608-611.
10. Cellerino R, Tummarello D, Guidi F et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991;9:1453-1461.
11. Ginsberg R, Vokes EE, Raben A Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology (5th ed). Philadelphia: Lippincott, 1997: 895-910.
12. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B. J Natl Cancer Inst 1996;88:1210-1215.
13. Le Chevalier T, Arriagada R, Tarayre M et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma [letter]. J Natl Cancer Inst 1992;84:58.
14. Sause WT, Scott C, Taylor S et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
15. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-530.
16. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 1993; 11:1391-1402.
17. Feigal EG, Christian M, Cheson B et al. New chemotherapeutic agents in non-small-cell lung cancer. Semin Oncol 1993;20:185-201.
18. Le Chevalier T, Brisgand D, Douillard J-Y et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367.
19. Chang AY, Kim K, Glick J et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-394.
20. Murphy WK, Fossella FV, Winn RJ et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-388.
21. Fishbein GE. Immunotherapy of lung cancer. Semin Oncol 1993; 20:351-358.
22. Howard M, Farrar J, Hilfiker M et al. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 1982;155:914-923.
23. Yokota T, Otsuka T, Mosmann T et al. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc Natl Acad Sci U S A 1986;83:5894-5898.
24. Spits H, ed. IL-4: Structure and Function. Boca Raton, FL: CRC Press, 1993:15-32.
25. Lewis DB, Prickett KS, Larsen A et al. Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci U S A 1988;85:9743-9747.
26. King AG, Wierda D, Landreth KS. Bone marrow stromal cell regulation of B-lymphopoiesis. I. The role of macrophages, IL-1, and IL-4 in pre-B cell maturation. J Immunol 1988;141:2016-2026.
27. Defrance T, Vanbervliet B, Pene J et al. Human recombinant IL-4 induces activated B lymphocytes to produce IgG and IgM. J Immunol 1988;141:2000-2005.
28. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236:944-947.
29. Pene J, Rousset F, Briere F et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A 1988;85:6880-6884.
30. Paliard X, Malefijt RW, de Vries JE et al. Interleukin-4 mediates CD8 induction on human CD4+ T-cell clones. Nature 1988; 335:642-644.
31. Kawakami Y, Custer MC, Rosenberg SA et al. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol 1989;142:3452-3461.
32. Treisman J, Higuchi CM, Thompson JA et al. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients. Cancer Res 1990;50:1160-1164.
33. Abramson SL, Gallin JI. IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol 1990;144:625-630.
34. Standiford TJ, Strieter RM, Chensue SW et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol 1990;145:1435-1439.
35. Baskar P, Silberstein DS, Pincus SH. Inhibition of IgG-triggered human eosinophil function by IL-4. J Immunol 1990;144:2321-2326.
36. Moser R, Groscurth P, Carballido JM et al. Interleukin-4 induces tissue eosinophilia in mice: correlation with its in vitro capacity to stimulate the endothelial cell-dependent selective transmigration of human eosinophils. J Lab Clin Med 1993;122:567-575.
37. Plunket. Schering-Plough Research Institute data on file.
38. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-512.
39. Golumbek PT, Lazenby AJ, Levitsky HI et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716.
40. Hunt JD, Pippin BA, Landreneau RJ et al. Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. J Immunother 1993; 14:314-321.
41. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992;257: 548-551.
42. Pericle F, Giovarelli M, Colombo MP et al. An efficient Th-2 type memory follows CD8+ lymphocyte driven and eosinophil mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-5673.
43. Morisaki T, Yuzuki DH, Lin RT et al. Interleukin-4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin-4. Cancer Res 1992;52:6059-6065.
44. Hoon DS, Hayashi Y, Morisaki T et al. Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. Cancer Immunol Immunother 1993;37:378-384.
45. Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-279.
46. Obiri NI, Siegel JP, Varricchio F et al. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 1994;95:148-155.
47. Obiri NI, Hillman GG, Haas GP et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93.
48. Kaklamanis L, Gatter KC, Mortensen N et al. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br J Cancer 1992;66:712-716.
49. Morisaki T, Uchiyama A, Yuzuki D et al. Interleukin-4 regulated G1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994;54:1113-1118.
50. Topp MS, Loenigsmann M, Mire-Sluis A et al. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 1993;82:2837-2844.
51. Tungekar MF, Turley H, Dunnill MS et al. Interleukin-4 receptor expression on human lung tumors and normal lung. Cancer Res 1991;51:261-264.
52. Gilleece MH, Scarffe JH, Ghosh A et al. Recombinant human interleukin-4 (IL-4) given as daily subcutaneous injections - a phase I dose toxicity trial. Br J Cancer 1992;66:204-210.
53. Prendiville J, Thatcher N, Lind M et al. Recombinant human interleukin-4 (rHu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer - a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer 1993;29A: 1700-1707.
54. Margolin K, Aronson FR, Sznol M et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother 1994;15:147-153.
55. Fuks JZ, Egorin MJ, Aisner J et al. Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol 1983;10:104-108.
56. Olver IN, Donehower RC, Van Echo DA et al. Phase II trial of carboplatin in non-small cell lung cancer. Cancer Treatment Reports 1986;70:421-422.
57. Fossella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-651.
58. Burris H, Eckardt J, Fields S et al. Phase II trials of Taxotere in patients with non-small cell lung cancer [abstract]. Proceedings of ASCO 1993;12:335.
59. Gandara DR, Vokes EE, Green M et al. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial [abstract]. Proceedings of ASCO 1997;16:454a.
60. Murphy WK, Winn RJ, Huber M et al. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotherapy [abstract]. Proceedings of ASCO 1994;13:363.
61. Crino L, Mosconi AM, Scagliotti G et al. Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC) [abstract]. Proceedings of ASCO 1997;16: 446a.